Axsome Therapeutics
AXSM
167 hedge funds and large institutions have $704M invested in Axsome Therapeutics in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 57 reducing their positions, and 29 closing their positions.
181% more call options, than puts
Call options by funds: $141M | Put options by funds: $49.9M
12% more capital invested
Capital invested by funds: $627M → $704M (+$76.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.13% less ownership
Funds ownership: 50.59% → 49.47% (-1.1%)
2% less funds holding
Funds holding: 171 → 167 (-4)
12% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 57
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
Top Buyers
Top Sellers
AXSM Hedge Fund Activity: Q4 2021 in Review
167 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2021, worth a combined $704M — up 12% from $627M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of AXSM and 25 opened new positions — a net loss of 4 holders — while 57 trimmed existing stakes and 50 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $28.5M. The largest seller was Iridian Asset Management, cutting an estimated $29.9M.
- 167 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2021, down from 171 in Q3 2021.
- Funds reported $704M of Axsome Therapeutics stock for Q4 2021, up 12% quarter-over-quarter.
- 25 funds opened new Axsome Therapeutics positions in Q4 2021 and 29 closed out, a net change of -4 holders.
- The largest Axsome Therapeutics buyer in Q4 2021 was Avidity Partners Management, an estimated $28.5M added.
- The largest Axsome Therapeutics seller in Q4 2021 was Iridian Asset Management, an estimated $29.9M sold.
Based on aggregated 13F filings for Q4 2021.